Roth Capital Comments on Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Roth Capital issued their Q1 2025 EPS estimates for Nuvectis Pharma in a research report issued to clients and investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff anticipates that the company will earn ($0.23) per share for the quarter. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2028 earnings at $3.61 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

Nuvectis Pharma Stock Performance

NVCT opened at $8.34 on Wednesday. The company has a market cap of $155.54 million, a price-to-earnings ratio of -6.47 and a beta of 0.41. Nuvectis Pharma has a one year low of $5.85 and a one year high of $12.10. The business’s fifty day moving average is $6.84 and its two-hundred day moving average is $6.69.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same period in the previous year, the business posted ($0.37) EPS.

Institutional Trading of Nuvectis Pharma

Several institutional investors and hedge funds have recently modified their holdings of NVCT. Vanguard Group Inc. increased its stake in shares of Nuvectis Pharma by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock worth $2,450,000 after purchasing an additional 4,517 shares in the last quarter. Baldwin Brothers LLC MA grew its holdings in Nuvectis Pharma by 9.4% during the 2nd quarter. Baldwin Brothers LLC MA now owns 168,630 shares of the company’s stock valued at $1,067,000 after buying an additional 14,500 shares during the last quarter. Renaissance Technologies LLC increased its position in Nuvectis Pharma by 20.7% during the second quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock worth $472,000 after buying an additional 12,800 shares in the last quarter. Iridian Asset Management LLC CT purchased a new position in Nuvectis Pharma during the third quarter worth $348,000. Finally, GSA Capital Partners LLP raised its holdings in shares of Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after acquiring an additional 1,790 shares during the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.